Kowa (company)
Tracked across 3 events · 19 articles · First seen Apr 23, 2026 · Last active Sep 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Kowa (company) is NicOx's exclusive U.S. partner for NCX 470 and is expected to submit the New Drug Application for the drug in the U.S. in summer 2026. Kowa (company) bears the commercialization costs for its licensed territories.
Jun 18, 2026 · 7 articles
Business
Impact: Kowa (company) is NicOx's exclusive U.S. partner for NCX 470 and anticipates a commercial launch in H2 2027 subject to approval. The expected approval milestone and royalties are key to NicOx's extended runway.
Sep 02, 2026 · 6 articles
Regulatory
Impact: Kowa (company) is NicOx's partner for the rest of the world and recently submitted the U.S. NDA. Its regulatory progress is aligned with NicOx's commercialization strategy.
Aug 10, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Kowa (company) live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard